The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Kropz gets more cash; Audioboom releases new podcasts

Thu, 01st Sep 2022 21:55

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Open Orphan PLC - London-based pharmaceutical services - Its clinical laboratories in Queen Mary's Bioenterprise Centre and Plumbers Row wins accreditation by the College of American Pathologists. "The company sought the accreditation as part of its ongoing commitment to maintaining best in class quality systems," it explains.

----------

Audioboom Group PLC - London-based podcast producer - Expands its podcast network with the launch of three new shows from Audioboom Studios, the company's production arm. "Audioboom's continued investment into content development will further grow the company's intellectual property, deliver increased gross margins to the business, expand audience reach, and develop premium advertising inventory," it says. Launches 'Glittering A Turd' from Kris Hallenga, 'Killers, Cults and Queens' from Cheryl Hole and Nikki Druce, and 'Superpower State of Mind' from Malin Andersson.

----------

Sopheon PLC - Minnesota, US-based enterprise software provider - Updates management product Accolade. "Using Accolade, Sopheon's long-standing blue-chip customers across a diverse range of industries have experienced superior strategy-to-execution performance, reduced time-to-market, improved efficiency, and greater product success rate," it explains.

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Draws down GBP180,000 of the GBP10 million equity drawdown agreement with Crescita Capital LLC, which was originally entered into in February 2021. Shares issued at 1.5 pence each, seeing 12 million new shares issued. "The capital drawn down will be used to advance the company's acquisitions of energy royalties, lithium assets and bauxite projects globally," it explains.

----------

Power Metal Resources PLC - metals exploration company focused on North America, Africa and Australia - Wholly owned Australian subsidiary Power Metal Resources Australia sees confirmation of grant of exploration licence application 2021-000163, covering 999 square kilometres of ground in the Anna Creek area of South Australia. Exploration licence will last for 6 years, ending August 2028, and subject to minimum spend of AUD100,000, about GBP59,000. Chief Executive Paul Johnson says: "There is more work to do, clearly, and we are early stage here, however all projects of substance start early stage and the Wilan Project is off to a great start."

----------

Kropz PLC - African phosphate developer - Draws down ZAR47 million from recent bridge loan facility of ZAR121.5 million with major shareholder, the ARC Fund, to meet immediate cash requirements due to further delays in the ramp up of operations at Kropz Elandsfontein Ltd. "Progress continues to be made, however, in the ramp up," it adds. "Kropz and ARC Fund are currently working on a comprehensive funding structure to finance any further funding requirements in Kropz."

----------

Hummingbird Resources PLC - gold production, development and exploration focused on West Africa - Says development and construction of its second gold mine, Kouroussa, is now over 50% completed and remains on time and budget to achieve first gold pour by the end of the second quarter of 2023, which will more than double Hummingbird's gold production profile. Notes final assay results confirmed, with results showing 9.0 metres at 32.60 grammes per tonne gold from 116 metres.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2020 10:51

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Read more
16 Jan 2020 18:15

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Read more
14 Jan 2020 16:10

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Read more
6 Jan 2020 17:29

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 11:49

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 10:55

Open Orphan inks three-year contract with mystery European firm

(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.

Read more
31 Dec 2019 09:46

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Read more
31 Dec 2019 06:31

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Dec 2019 12:54

Open Orphan signs deal with US biopharmaceutical firm SFA

(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.

Read more
18 Dec 2019 12:29

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Read more
9 Dec 2019 14:36

Open Orphan agrees acquisition of hVIVO at 34% premium

(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.

Read more
9 Dec 2019 11:23

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Read more
25 Nov 2019 14:57

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Read more
18 Nov 2019 10:35

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Read more
18 Nov 2019 09:58

Open Orphan signs pharmacology trial contract with Carna

(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.